Enter to open, tab to navigate, enter to select
Antitrust risk-shifting provisions in Biogen Inc./Reata Pharmaceuticals, Inc. merger agreement
| July 28, 2023 • Antitrust Risk-shifting • $7.3 billion (enterprise value disclosed by the parties). |
End of Document
© 2024 Thomson Reuters. No claim to original U.S. Government Works.